A 8-year retrospective cohort study comparing Interferon-β formulations for relapsing‐remitting multiple sclerosis

Patients treated with Interferon-β1a 44 mcg presented with a marginally reduced risk of disability accrual in the long-term, when compared with Interferon-β1b 250 mcg and, at least in part, with Interferon-β1a 30 mcg. Formulation, frequency of administration and dose of Interferon-β might affect the long-term clinical evolution of RRMS.